Is the Race On for RNAi? A Chinese Pharma’s $450M Deal May Just Be the Start
siRNA, which operates via the RNA interference (RNAi) pathway, has the potential to silence disease-causing genes. When it is introduced into a cell, it assembles a “hit squad” -- an RNA-induced Silencing Complex (RISC) -- which looks for specific mRNA matching the siRNA's sequence. Once the target is found, the siRNA pairs with the mRNA, inducing cleavage. As the mRNA won't be translated into proteins, the action effectively puts a muffler on the gene that encodes the mRNA.
China's Hansoh Pharma believes the time is ripe to tap into gene silencing technology and has chosen to work with South Korea RNA Biotech OliX Pharmaceuticals in a deal worth over $450 million.
China's Hansoh Pharma believes the time is ripe to tap into gene silencing technology and has chosen to work with South Korea RNA Biotech OliX Pharmaceuticals in a deal worth over $450 million.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02